Risk factors of hepatotoxicity during anti-tuberculosis treatment

Medical Journal Armed Forces India

Volumn 62, Issue 1, 2006, Pages 45-49

  Anand, A C ^a   Seth, A K ^b   Paul, M ^c   Puri, P ^b  

^a ARMED FORCES MEDICAL COLLEGE   (India)

^b ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

^c Associated with Armed Forces Medical College   (India)

Author keywords

Antituberculosis treatment; Hepatotoxicity; Malnutrition

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; HEPATITIS B SURFACE ANTIGEN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ABDOMINAL DISCOMFORT; ADOLESCENT; ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANOREXIA; ARTICLE; BODY MASS; CHI SQUARE TEST; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; FEMALE; FISHER EXACT TEST; FOLLOW UP; GENDER; HEPATITIS B; HOSPITAL SERVICE; HUMAN; HYPERSENSITIVITY REACTION; INDIAN; JAUNDICE; LIVER DYSFUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NUTRITIONAL STATUS; PREDICTION; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TOXIC HEPATITIS; TUBERCULOSIS; VIRUS CARRIER; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 33344457609     PISSN: 03771237     EISSN: 03771237     Source Type: Journal    
DOI: 10.1016/S0377-1237(06)80155-3     Document Type: Article

References (30)

1. World Health Organization. Global Tuberculosis Control. WHO report, 2001. Geneva, Switzerland: WHO/CDS/TB;2001.287.
2. Mahashur AA, Prabhudesai PP. Hepatitis and antitubercular therapy. J Assoc Physicians India 1991; 39: 595-6.
3. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996; 22(3): 211-4.
4. Dull AK, Moers D. Slead WW. Short course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampicin: community physicians' seven-year experience with mainly outpatients. Am J Med 1984:77:233-42.
5. Steele MA, Burk RF, Desprez RM. Hepatitis with isoniazid and rifampicin; a meta-analysis. Chest 1991;99:465-71.
6. Taneja DP, Kaur D. Study on hepatotoxicity and other side effects of antituberculosis drugs. J Indian Med Assoc 1990; 88: 278-80.
7. Gurumurthy P, Krishnamurthy MS, Nazareth O,«t al. Lack of relationship between hepatic toxicity and acerylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129:58-61.
8. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of Clinical and Immunogenetic Risk Factors in the Development of Hepatotoxicity during Antituberculosis Treatment. Am J Respir Crit Care Med 2002; 166: 916-9.
9. Deshpande DV, Nachne D, Koyande D, Rodrigues CJ. Antitubercular treatment in patients with hepatitis. J Assoc Physicians India 1991;39:599-601.
10. Anand AC, Nagpal A, Seth AK. Liver dysfunction related to Anti-tuberculous treatment is more common in chronic hepatitis. JAssocPhysicians India 2002; 50[12], 1538-9.
11. National Institute of Nutrition. BMI and mortality rate-a 10 year prospective study. National Institute of Nutrition Annual Report, 1989, pp 1-13.
12. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004; 38(6):1074-9.
13. Pande JN, Singh SPN, Khilnani GC, Tandon RK. Risk factors for hepatotoxicity from antituberculous drugs: a case control study. Thorax 1996; 51: 132-6.
14. Gangadharan PRJ. Isoniazid. rifampicin and hepatotoxicity. Am J Respir Dis 1986; 133: 963-5.
15. Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Antituberculosis treatment induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995; 71: 359-62.
16. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37(4):924-30.
17. Gronhagen-Riska C, Hellstrom PE, Froscth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118: 461-6.
18. Wu JC, Lee SD, Yeh PF et al. Isoniazid-rifampin induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98: 502-4.
19. McGlynn KA, Lustbader ED, Sharrar RG; Murphy EC, London WT.Isoniazid prophylaxis in hepatitis B carriers. Am Rev Respir Dis. 1986 Oct; 134(4): 666-8.
20. Ansari MM, Beg MH, Haleem, S. Hepatitis in patients with surgical complications of pulmonary tuberculosis. Indian J Chest Dis Allied Sci 1991; 33: 133-8.
21. Buchanan N, Eyberg C, David MD. Isoniazid pharmacokinetics in kwashiorkor. S Afr Med J 1979; 56: 299-300.
22. Kumar A, Misra PK, Mehrolra R, Govil YC, Rana GS. Hepatotoxicity of rifampicin and isoniazid: is it all drug induced hepatitis? Am Rev Respir Dis 1991; 143: 1350-2.
23. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-asscciated hepatitis in 114 patients. Gastroenterology 1975; 69: 289-302.
24. Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis 1989; 140:700-5.
25. Kunimoto D, Warman A, Beckon A, Doering D, Melenka L. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity. Clin Infect Dis 2003; 36(12):e158-e161.
26. Maddrey WC. Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973;79:1-12.
27. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 2002; 6(11): 995-1000.
28. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137(8):640-7.
29. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167(11): 1472-7.
30. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003; 123(1):102-6.